Premium
Two‐weekly dose‐adjusted ( DA )‐ EPOCH ‐like chemotherapy with high‐dose dexamethasone plus rituximab ( DA ‐ EDOCH 14‐ R ) in poor‐prognostic untreated diffuse large B ‐cell lymphoma
Author(s) -
GarcíaSuárez Julio,
Flores Elena,
Callejas Marta,
Arribas Ignacio,
GilFernández JuanJosé,
Olmedilla Gabriel,
Curto Natalia,
Guillén Helga,
Casco CeliaRosalva,
Martín Yolanda,
Burgaleta Carmen
Publication year - 2013
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12144
Subject(s) - medicine , vincristine , rituximab , chemotherapy , etoposide , dexamethasone , cyclophosphamide , international prognostic index , prednisone , gastroenterology , epoch (astronomy) , oncology , lymphoma , stars , physics , astronomy
Summary The activity and safety of two‐weekly dose‐adjusted ( DA )‐ EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin)‐like chemotherapy with high‐dose dexamethasone plus rituximab ( DA ‐ EDOCH 14‐ R ) was explored in 20 patients with previously untreated poor prognosis diffuse large B ‐cell lymphoma ( DLBCL ). The main outcomes were compared with those of 27 poor‐prognosis patients enrolled into a previous trial of 3‐weekly DA ‐ EPOCH ‐ R . Toxicity was manageable and there were no therapy‐related deaths. Three‐year progression‐free survival ( PFS ) was superior in the DA ‐ EDOCH 14‐ R group (95% vs. 74%, P = 0·08). Importantly, this improvement in PFS with the two‐weekly DA ‐ EDOCH 14‐ R was particularly notable in patients with an age‐adjusted International Prognostic Index of 3 (100% vs. 30%, P < 0·001).